666 related articles for article (PubMed ID: 17267582)
1. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
2. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Wang D; Raehal KM; Bilsky EJ; Sadée W
J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
[TBL] [Abstract][Full Text] [Related]
3. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
4. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
5. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
[TBL] [Abstract][Full Text] [Related]
6. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
[TBL] [Abstract][Full Text] [Related]
7. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
8. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
10. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
11. Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes.
Breivogel CS; Selley DE; Childers SR
J Neurochem; 1997 Apr; 68(4):1462-72. PubMed ID: 9084416
[TBL] [Abstract][Full Text] [Related]
12. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
[TBL] [Abstract][Full Text] [Related]
13. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.
Divin MF; Bradbury FA; Carroll FI; Traynor JR
Br J Pharmacol; 2009 Apr; 156(7):1044-53. PubMed ID: 19220294
[TBL] [Abstract][Full Text] [Related]
14. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
[TBL] [Abstract][Full Text] [Related]
15. Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.
Szekeres PG; Traynor JR
J Pharmacol Exp Ther; 1997 Dec; 283(3):1276-84. PubMed ID: 9400003
[TBL] [Abstract][Full Text] [Related]
16. The stimulatory effect of mu- and delta-opioid receptors on bovine pinealocyte melatonin synthesis.
Chuchuen U; Ebadi M; Govitrapong P
J Pineal Res; 2004 Nov; 37(4):223-9. PubMed ID: 15485547
[TBL] [Abstract][Full Text] [Related]
17. Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
Sim LJ; Childers SR
J Comp Neurol; 1997 Oct; 386(4):562-72. PubMed ID: 9378852
[TBL] [Abstract][Full Text] [Related]
18. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological effects of naltriben as a ligand for opioid mu and kappa receptors in rat cerebral cortex.
Kim KW; Son Y; Shin BS; Cho KP
Life Sci; 2001 Feb; 68(11):1305-15. PubMed ID: 11233997
[TBL] [Abstract][Full Text] [Related]
20. Selective and interactive down-regulation of mu- and delta-opioid receptors in human neuroblastoma SK-N-SH cells.
Baumhaker Y; Gafni M; Keren O; Sarne Y
Mol Pharmacol; 1993 Aug; 44(2):461-7. PubMed ID: 8394999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
